Dr. Reddy's shares jump over 3% following Q1 results – Should you buy, hold or sell? Know More
Shares of Dr. Reddy's Laboratories surged 3.06% to Rs 1,285.60 on Wednesday after the company reported its Q1 FY26 financial results. The stock touched an intraday high of Rs 1,287.90 and now commands a market capitalization of Rs 1.07 lakh crore.
For the quarter ended June 30, 2025, the pharmaceutical major posted a consolidated net profit of Rs 1,418 crore, up 2% year-on-year. Revenue from operations stood at Rs 8,545 crore, reflecting an 11% YoY increase, primarily driven by contributions from the acquired Nicotine Replacement Therapy (NRT) portfolio and steady performance in branded markets.
However, profit declined 11% quarter-on-quarter, while revenue remained flat sequentially. EBITDA for the quarter was Rs 2,280 crore, marking a 5% YoY increase, though EBITDA margin slipped 530 basis points to 56.9%, largely due to pricing pressure in the US generics segment and lower operating leverage.
The Global Generics segment recorded Rs 7,560 crore in revenue, up 10% YoY, but remained unchanged QoQ. Revenue from North America declined 11% YoY to Rs 3,410 crore amid price erosion in key generics like Lenalidomide.
Meanwhile, India revenue grew 11% YoY to Rs 1,470 crore, aided by new launches and pricing strategies. European business saw a sharp 142% YoY jump to Rs 1,270 crore, driven by the NRT acquisition and product launches.
Brokerages offered a cautious outlook on Dr. Reddy's Laboratories following its Q1 FY26 results, primarily due to concerns over the US generics business. CLSA and Jefferies both retained their 'Underperform' ratings, with target prices of Rs 1,120 and Rs 1,100 respectively. CLSA noted that while overall earnings were in line with expectations, the US base business is expected to remain flat or grow in low single digits year-on-year, with Revlimid sales likely tapering off from Q3FY26. Jefferies flagged a miss in Q1 estimates due to a sharper-than-expected decline in US sales, driven by lower revenues from gRevlimid and sustained pressure in the base portfolio. Elevated SG&A and R&D spending also weighed on margins. However, it highlighted upcoming launches such as gOzempic in Canada and the US filing for Abatacept as key triggers to watch. Meanwhile, Morgan Stanley maintained an 'Equal-weight' rating with a target price of Rs 1,298, acknowledging steady growth in most markets but citing generic price erosion and reduced operating leverage as drag factors on margin.
Dr. Reddy's Q1 YoY Comparison Table (in Rs crore): Metric Q1 FY26 Q1 FY25 YoY % Change Revenue from Operations 8,545 7,700 11% Net Profit 1,418 1,390 2% EBITDA 2,280 2,170 5% EBITDA Margin (%) 56.9% 62.2% -530 bps
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Credit Agricole's Asset Servicing Unit Backs Tokenized SME Exchange in Europe
CACEIS, the asset servicing arm of Credit Agricole, has acquired a minority stake in French fintech Kriptown to support the launch of Lise, a blockchain-based exchange aimed at SMEs and mid-cap companies. Lise, short for Lightning Stock Exchange, is set to be Europe's first tokenized exchange focused on streamlining equity financing and public listings for smaller firms, CACEIS said in a press release on Monday. Lise is currently awaiting regulatory approval as a DLT Trading and Settlement System (DLT TSS) under the European pilot regime. If approved, it would allow companies to issue, trade, and settle financial instruments directly on a distributed ledger, cutting down the time and costs associated with traditional IPO processes. Lise would allow investors to trade shares on a secondary market that operates around the clock, without the bottlenecks of standard clearing houses, or lengthy coordination of multiple intermediaries. The move aligns with CACEIS's broader push into digital assets, which saw it receive MiCA approval earlier this year. Founded in 2018, Kriptown develops infrastructure for tokenizing financial instruments, integrating both market and post-trade operations. Lise's first IPO is planned for 2025, contingent on receiving the necessary while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Upturn
2 hours ago
- Business Upturn
Airtel launches sovereign cloud and AI software platform under Xtelify to power global telcos
By Aditya Bhagchandani Published on August 4, 2025, 14:35 IST Bharti Airtel's digital arm, Xtelify, unveiled two major digital initiatives on August 4, 2025 — a sovereign, telco-grade cloud platform named Airtel Cloud and an AI-powered software suite aimed at revolutionizing digital transformation for telecom operators globally. The newly launched Airtel Cloud, built in India and hosted on sustainable data centres, is designed to handle up to 140 crore transactions per minute. It assures up to 40% cloud spend optimization for Indian businesses, with offerings across IaaS, PaaS, and secure connectivity — all managed by 300 certified cloud professionals. Alongside, Xtelify also launched a suite of AI-based software solutions tailored for telcos, featuring components like Data Engine, Xtelify Work, and Xtelify IQ to improve customer experience, streamline operations, and boost productivity. Xtelify has already partnered with three major players: Singtel (Singapore) for AI-enabled field management via Xtelify Work for AI-enabled field management via Globe Telecom (Philippines) for omni-channel customer service through Xtelify Serve for omni-channel customer service through Airtel Africa across 14 countries for field operations and fraud protection Gopal Vittal, Vice Chairman and MD of Bharti Airtel, said the initiative aims to help Indian enterprises and global telcos innovate faster and scale smarter, all while maintaining data sovereignty. Disclaimer: The information provided is for informational purposes only and does not constitute financial or investment advice. Always conduct your own research before making business decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
2 hours ago
- Business Upturn
EIH Associated Hotels Q1 Results: Net profit up 72.5% YoY to Rs 61.76 crore
EIH Associated Hotels, part of the Oberoi Group, reported a strong 72.5% year-on-year (YoY) increase in net profit for the quarter ended June 30, 2025 (Q1 FY26), with profit after tax rising to Rs 61.76 crore from Rs 35.98 crore in the same period last year. The company's total income for the quarter stood at Rs 736.81 crore, up 6.8% from Rs 689.76 crore in Q1 FY25. Revenue from operations increased to Rs 687.43 crore, compared to Rs 644.81 crore in the corresponding quarter of the previous fiscal. Other income also rose to Rs 49.37 crore from Rs 44.99 crore last year. Total expenses came in at Rs 640.87 crore, up from Rs 614.91 crore in Q1 FY25. The rise was driven by higher consumption of provisions (Rs 57.56 crore), employee benefit expenses (Rs 174.61 crore), and depreciation and amortisation (Rs 36.54 crore). Profit before tax stood at Rs 82.82 crore, up 71.6% YoY. However, the company saw a jump in tax expenses at Rs 21.06 crore compared to Rs 12.47 crore in Q1 FY25. Sequentially, the company's performance declined as revenue fell from Rs 1,399.1 crore in Q4 FY25 and net profit dropped from Rs 462.7 crore in the previous quarter. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
